Evaluation of Interferon-gamma Release Assay in Children with Confirmed Tuberculosis

Q3 Medicine

Pediatric Infection and Vaccine Pub Date : 2021-04-01 DOI:10.14776/PIV.2021.28.E5

Kyu Ho Kim, Ji‐Man Kang, Jong Gyun Ahn

{"title":"Evaluation of Interferon-gamma Release Assay in Children with Confirmed Tuberculosis","authors":"Kyu Ho Kim, Ji‐Man Kang, Jong Gyun Ahn","doi":"10.14776/PIV.2021.28.E5","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to evaluate the diagnostic value of the QuantiFERON-TB Gold InTube (QFT-GIT) in children with confirmed tuberculosis (TB). Methods: We retrospectively reviewed the medical records of children aged ≤18 years who underwent both QFT-GIT and Mycobacterium tuberculosis culture between 2006 and 2017. Confirmed TB was defined as the presence of at least one positive specimen for M. tuberculosis on culture or a nucleic acid amplification test. Results: Of the 582 patients included in the analysis, 48 were confirmed to have TB. The sensitivity and specificity of QFT-GIT for the diagnosis of confirmed TB were 85.4% and 95.5%, respectively. Among children with confirmed TB, the proportion in the immunocompromised state was higher in the QFT-GIT negative group than in the QFT-GIT positive group (50.0% vs. 5.7%, P=0.010). The median age at sampling was lower in the QFTGIT indeterminate group than in the QFT-GIT positive group (7 years vs. 17 years, P=0.008), and the proportion of immunosuppression was higher in the QFT-GIT indeterminate group than in the QFT-GIT positive group (42.9% vs. 5.7%, P=0.017). The interferon gamma response to mitogen control was significantly higher in the 10–18 years group than in the 0–9 years group (P<0.001), and was significantly higher in the immunocompetent group than in the immunocompromised group (P=0.001). Conclusion: The QFT-GIT results should be interpreted carefully in immunocompromised or younger children suspected of having TB.","PeriodicalId":37997,"journal":{"name":"Pediatric Infection and Vaccine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Infection and Vaccine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14776/PIV.2021.28.E5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to evaluate the diagnostic value of the QuantiFERON-TB Gold InTube (QFT-GIT) in children with confirmed tuberculosis (TB). Methods: We retrospectively reviewed the medical records of children aged ≤18 years who underwent both QFT-GIT and Mycobacterium tuberculosis culture between 2006 and 2017. Confirmed TB was defined as the presence of at least one positive specimen for M. tuberculosis on culture or a nucleic acid amplification test. Results: Of the 582 patients included in the analysis, 48 were confirmed to have TB. The sensitivity and specificity of QFT-GIT for the diagnosis of confirmed TB were 85.4% and 95.5%, respectively. Among children with confirmed TB, the proportion in the immunocompromised state was higher in the QFT-GIT negative group than in the QFT-GIT positive group (50.0% vs. 5.7%, P=0.010). The median age at sampling was lower in the QFTGIT indeterminate group than in the QFT-GIT positive group (7 years vs. 17 years, P=0.008), and the proportion of immunosuppression was higher in the QFT-GIT indeterminate group than in the QFT-GIT positive group (42.9% vs. 5.7%, P=0.017). The interferon gamma response to mitogen control was significantly higher in the 10–18 years group than in the 0–9 years group (P<0.001), and was significantly higher in the immunocompetent group than in the immunocompromised group (P=0.001). Conclusion: The QFT-GIT results should be interpreted carefully in immunocompromised or younger children suspected of having TB.

查看原文本刊更多论文

儿童结核确诊患者干扰素释放试验的评价

目的：本研究旨在评估QuantiFERON TB金管（QFT-GIT）对儿童确诊结核病（TB）的诊断价值。方法：我们回顾性回顾了2006年至2017年间接受QFT-GIT和结核分枝杆菌培养的≤18岁儿童的医疗记录。确诊结核病是指在培养或核酸扩增测试中至少存在一个结核分枝杆菌阳性标本。结果：在纳入分析的582名患者中，48人被证实患有结核病。QFT-GIT诊断结核的敏感性和特异性分别为85.4%和95.5%。在确诊结核病的儿童中，QFT-GIT阴性组免疫功能低下的比例高于QFT-GIT阳性组（50.0%对5.7%，P=0.010）。QFTGIT不确定组的中位抽样年龄低于QFT-GI特阳性组（7岁对17岁，P=0.008），QFT-GIT不确定组的免疫抑制比例高于QFT-GIT阳性组（42.9%对5.7%，P=0.017）。10–18岁组对有丝分裂原控制的干扰素-γ反应显著高于0–9岁组（P<0.001），免疫功能组的QFT-GIT结果明显高于免疫功能低下组（P=0.001）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Infection and Vaccine Medicine-Pediatrics, Perinatology and Child Health

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： Pediatric Infection and Vaccine is an official publication of the Korean Society of Pediatric Infectious Diseases and a peer-reviewed, open-access, multidisciplinary journal directed to physicians and other health care professionals who manage infectious diseases of childhood. The editorial board calls for the articles that originate from worldwide research or clinical study groups and the publication is determined by the editors and reviewers who are the experts in the specific field of infectious diseases of childhood. The categories of manuscripts are original articles, case reports, reviews and rapid communication. The Journal is published triannually and distributed to members of the Korean Society of Pediatric Infectious Diseases, medical schools, libraries and related institutes to persue the academic advancement in infectious diseases and to promote active communication between the members and international societies of pediatric infectious diseases. Eventually, the journal aims to contribute to the cure of infectious diseases of childhood and to the improvement of public health.